{"id":58645,"date":"2026-03-03T13:38:01","date_gmt":"2026-03-03T05:38:01","guid":{"rendered":"https:\/\/flcube.com\/?p=58645"},"modified":"2026-03-03T13:38:02","modified_gmt":"2026-03-03T05:38:02","slug":"nanjing-novlead-bio-files-hong-kong-ipo-nitric-oxide-therapy-specialist-targets-critical-care-market","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=58645","title":{"rendered":"Nanjing Novlead Bio Files Hong Kong IPO \u2013 Nitric Oxide Therapy Specialist Targets Critical Care Market"},"content":{"rendered":"\n<p><strong>Nanjing Novlead Biotechnology Co., Ltd.<\/strong>, a <strong>nitric oxide (NO) gas detection and treatment specialist<\/strong>, filed for an <strong>initial public offering (IPO)<\/strong> on the <strong>Hong Kong Stock Exchange<\/strong>. Founded in <strong>2018<\/strong>, the company has established <strong>three product lines<\/strong>\u2014<strong>iNO therapy, cardiopulmonary circulatory support, and exhaled breath diagnostics<\/strong>\u2014with <strong>five approved products<\/strong> and <strong>four pipeline candidates<\/strong> spanning <strong>critical care, hospital wards, outpatient services, and home disease management<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-ipo-overview\">IPO Overview<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Company<\/strong><\/td><td>Nanjing Novlead Biotechnology Co., Ltd.<\/td><\/tr><tr><td><strong>Specialization<\/strong><\/td><td>Nitric oxide gas detection and treatment<\/td><\/tr><tr><td><strong>IPO Venue<\/strong><\/td><td>Hong Kong Stock Exchange<\/td><\/tr><tr><td><strong>Founded<\/strong><\/td><td>2018<\/td><\/tr><tr><td><strong>Product Lines<\/strong><\/td><td>3 (iNO therapy, cardiopulmonary circulatory support, exhaled breath diagnostics)<\/td><\/tr><tr><td><strong>Approved Products<\/strong><\/td><td>5<\/td><\/tr><tr><td><strong>Pipeline Candidates<\/strong><\/td><td>4<\/td><\/tr><tr><td><strong>Market Coverage<\/strong><\/td><td>Critical care, hospital wards, outpatient, home management<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-core-products\">Core Products<\/h2>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-inowill-inhaled-nitric-oxide-therapy\">iNOwill \u2013 Inhaled Nitric Oxide Therapy<\/h3>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Feature<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Technology<\/strong><\/td><td>World&#8217;s first <strong>electrochemical catalysis<\/strong> iNO therapy device<\/td><\/tr><tr><td><strong>Regulatory Status<\/strong><\/td><td>NMPA approved (2022); <strong>CE marked (EU, 2025)<\/strong><\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Acute critical care of severe cardiopulmonary diseases (pulmonary hypertension)<\/td><\/tr><tr><td><strong>Differentiation<\/strong><\/td><td>Electrochemical catalysis method vs. traditional cylinder\u2011based delivery<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h3 class=\"wp-block-heading\" id=\"h-novapulse-intra-aortic-balloon-pump-iabp\">NovaPulse Intra\u2011Aortic Balloon Pump (IABP)<\/h3>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Feature<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Technology<\/strong><\/td><td><strong>First domestically manufactured pneumatic IABP<\/strong> in China<\/td><\/tr><tr><td><strong>Regulatory Status<\/strong><\/td><td>NMPA approved for marketing<\/td><\/tr><tr><td><strong>Clinical Settings<\/strong><\/td><td>Operating rooms, ICUs, catheterization labs<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Temporary mechanical circulatory support for cardiovascular and perioperative care<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-implications\">Strategic Implications<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Critical Care Focus:<\/strong> Novlead&#8217;s <strong>iNO therapy and mechanical circulatory support<\/strong> products address <strong>high\u2011acuity, life\u2011threatening conditions<\/strong> with limited effective alternatives, supporting <strong>premium pricing and hospital formulary priority<\/strong>.<\/li>\n\n\n\n<li><strong>Domestic Manufacturing Advantage:<\/strong> <strong>First domestically produced pneumatic IABP<\/strong> reduces import dependence and aligns with China&#8217;s <strong>medical device localization policies<\/strong>, potentially securing <strong>procurement preferences<\/strong> in public hospitals.<\/li>\n\n\n\n<li><strong>Electrochemical Innovation:<\/strong> <strong>iNOwill&#8217;s electrochemical catalysis<\/strong> eliminates <strong>cylinder storage and logistics challenges<\/strong>, enabling <strong>point\u2011of\u2011care NO generation<\/strong> with improved safety and workflow efficiency.<\/li>\n\n\n\n<li><strong>IPO Growth Capital:<\/strong> <strong>Hong Kong listing<\/strong> provides <strong>international investor access<\/strong> and <strong>capital for pipeline expansion<\/strong>, including <strong>exhaled breath diagnostics<\/strong> for <strong>non\u2011invasive disease monitoring<\/strong>.<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-context\">Market Context<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Factor<\/th><th>Impact<\/th><\/tr><\/thead><tbody><tr><td><strong>iNO Therapy Market<\/strong><\/td><td>~\u202f$500\u202fmillion globally; pulmonary hypertension and hypoxic respiratory failure in neonates\/ICU settings<\/td><\/tr><tr><td><strong>IABP Market<\/strong><\/td><td>~\u202f$400\u202fmillion; dominated by Maquet (Getinge) and Teleflex; domestic Chinese production disrupts import\u2011dependent market<\/td><\/tr><tr><td><strong>Critical Care Device Growth<\/strong><\/td><td>Post\u2011pandemic ICU investment surge; China expanding critical care infrastructure in tier\u20112\/3 cities<\/td><\/tr><tr><td><strong>Breath Diagnostics Opportunity<\/strong><\/td><td>Exhaled NO and volatile organic compound analysis emerging for asthma, COPD, and infectious disease screening<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding IPO pricing, listing timeline, and commercial expansion for Novlead&#8217;s product portfolio. Actual results may differ due to risks including Hong Kong market volatility, competitive device launches, and regulatory inspection outcomes for manufacturing facilities.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Nanjing Novlead Biotechnology Co., Ltd., a nitric oxide (NO) gas detection and treatment specialist, filed&#8230;<\/p>\n","protected":false},"author":1,"featured_media":58646,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10,22],"tags":[72,2715],"class_list":["post-58645","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","category-medical-device","tag-ipo","tag-novlead-biotech"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.4) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Nanjing Novlead Bio Files Hong Kong IPO \u2013 Nitric Oxide Therapy Specialist Targets Critical Care Market - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Nanjing Novlead Biotechnology Co., Ltd., a nitric oxide (NO) gas detection and treatment specialist, filed for an initial public offering (IPO) on the Hong Kong Stock Exchange. Founded in 2018, the company has established three product lines\u2014iNO therapy, cardiopulmonary circulatory support, and exhaled breath diagnostics\u2014with five approved products and four pipeline candidates spanning critical care, hospital wards, outpatient services, and home disease management.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=58645\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Nanjing Novlead Bio Files Hong Kong IPO \u2013 Nitric Oxide Therapy Specialist Targets Critical Care Market\" \/>\n<meta property=\"og:description\" content=\"Nanjing Novlead Biotechnology Co., Ltd., a nitric oxide (NO) gas detection and treatment specialist, filed for an initial public offering (IPO) on the Hong Kong Stock Exchange. Founded in 2018, the company has established three product lines\u2014iNO therapy, cardiopulmonary circulatory support, and exhaled breath diagnostics\u2014with five approved products and four pipeline candidates spanning critical care, hospital wards, outpatient services, and home disease management.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=58645\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-03-03T05:38:01+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-03-03T05:38:02+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/0304.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58645#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58645\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Nanjing Novlead Bio Files Hong Kong IPO \u2013 Nitric Oxide Therapy Specialist Targets Critical Care Market\",\"datePublished\":\"2026-03-03T05:38:01+00:00\",\"dateModified\":\"2026-03-03T05:38:02+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58645\"},\"wordCount\":433,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58645#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/0304.webp\",\"keywords\":[\"IPO\",\"Novlead Biotech\"],\"articleSection\":[\"Company\",\"Deals\",\"Medical Device\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=58645#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58645\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=58645\",\"name\":\"Nanjing Novlead Bio Files Hong Kong IPO \u2013 Nitric Oxide Therapy Specialist Targets Critical Care Market - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58645#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58645#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/0304.webp\",\"datePublished\":\"2026-03-03T05:38:01+00:00\",\"dateModified\":\"2026-03-03T05:38:02+00:00\",\"description\":\"Nanjing Novlead Biotechnology Co., Ltd., a nitric oxide (NO) gas detection and treatment specialist, filed for an initial public offering (IPO) on the Hong Kong Stock Exchange. Founded in 2018, the company has established three product lines\u2014iNO therapy, cardiopulmonary circulatory support, and exhaled breath diagnostics\u2014with five approved products and four pipeline candidates spanning critical care, hospital wards, outpatient services, and home disease management.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58645#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=58645\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58645#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/0304.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/03\\\/0304.webp\",\"width\":1080,\"height\":608,\"caption\":\"Nanjing Novlead Bio Files Hong Kong IPO \u2013 Nitric Oxide Therapy Specialist Targets Critical Care Market\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=58645#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Nanjing Novlead Bio Files Hong Kong IPO \u2013 Nitric Oxide Therapy Specialist Targets Critical Care Market\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Nanjing Novlead Bio Files Hong Kong IPO \u2013 Nitric Oxide Therapy Specialist Targets Critical Care Market - Insight, China&#039;s Pharmaceutical Industry","description":"Nanjing Novlead Biotechnology Co., Ltd., a nitric oxide (NO) gas detection and treatment specialist, filed for an initial public offering (IPO) on the Hong Kong Stock Exchange. Founded in 2018, the company has established three product lines\u2014iNO therapy, cardiopulmonary circulatory support, and exhaled breath diagnostics\u2014with five approved products and four pipeline candidates spanning critical care, hospital wards, outpatient services, and home disease management.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=58645","og_locale":"en_US","og_type":"article","og_title":"Nanjing Novlead Bio Files Hong Kong IPO \u2013 Nitric Oxide Therapy Specialist Targets Critical Care Market","og_description":"Nanjing Novlead Biotechnology Co., Ltd., a nitric oxide (NO) gas detection and treatment specialist, filed for an initial public offering (IPO) on the Hong Kong Stock Exchange. Founded in 2018, the company has established three product lines\u2014iNO therapy, cardiopulmonary circulatory support, and exhaled breath diagnostics\u2014with five approved products and four pipeline candidates spanning critical care, hospital wards, outpatient services, and home disease management.","og_url":"https:\/\/flcube.com\/?p=58645","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-03-03T05:38:01+00:00","article_modified_time":"2026-03-03T05:38:02+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/0304.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=58645#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=58645"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Nanjing Novlead Bio Files Hong Kong IPO \u2013 Nitric Oxide Therapy Specialist Targets Critical Care Market","datePublished":"2026-03-03T05:38:01+00:00","dateModified":"2026-03-03T05:38:02+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=58645"},"wordCount":433,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=58645#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/0304.webp","keywords":["IPO","Novlead Biotech"],"articleSection":["Company","Deals","Medical Device"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=58645#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=58645","url":"https:\/\/flcube.com\/?p=58645","name":"Nanjing Novlead Bio Files Hong Kong IPO \u2013 Nitric Oxide Therapy Specialist Targets Critical Care Market - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=58645#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=58645#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/0304.webp","datePublished":"2026-03-03T05:38:01+00:00","dateModified":"2026-03-03T05:38:02+00:00","description":"Nanjing Novlead Biotechnology Co., Ltd., a nitric oxide (NO) gas detection and treatment specialist, filed for an initial public offering (IPO) on the Hong Kong Stock Exchange. Founded in 2018, the company has established three product lines\u2014iNO therapy, cardiopulmonary circulatory support, and exhaled breath diagnostics\u2014with five approved products and four pipeline candidates spanning critical care, hospital wards, outpatient services, and home disease management.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=58645#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=58645"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=58645#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/0304.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/0304.webp","width":1080,"height":608,"caption":"Nanjing Novlead Bio Files Hong Kong IPO \u2013 Nitric Oxide Therapy Specialist Targets Critical Care Market"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=58645#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Nanjing Novlead Bio Files Hong Kong IPO \u2013 Nitric Oxide Therapy Specialist Targets Critical Care Market"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/03\/0304.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/58645","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=58645"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/58645\/revisions"}],"predecessor-version":[{"id":58647,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/58645\/revisions\/58647"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/58646"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=58645"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=58645"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=58645"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}